FBLG vs. PTGX, EWTX, EVO, TARO, ARDX, SDGR, KURA, DVAX, MORF, and AVDL
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Protagonist Therapeutics (PTGX), Edgewise Therapeutics (EWTX), Evotec (EVO), Taro Pharmaceutical Industries (TARO), Ardelyx (ARDX), Schrödinger (SDGR), Kura Oncology (KURA), Dynavax Technologies (DVAX), Morphic (MORF), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry.
FibroBiologics (NASDAQ:FBLG) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
FibroBiologics has higher earnings, but lower revenue than Protagonist Therapeutics.
Protagonist Therapeutics has a consensus target price of $38.00, indicating a potential upside of 34.99%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than FibroBiologics.
In the previous week, Protagonist Therapeutics had 3 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Protagonist Therapeutics and 1 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 1.19 beat Protagonist Therapeutics' score of 0.71 indicating that FibroBiologics is being referred to more favorably in the media.
98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Protagonist Therapeutics received 261 more outperform votes than FibroBiologics when rated by MarketBeat users.
Protagonist Therapeutics' return on equity of 43.42% beat FibroBiologics' return on equity.
Summary
Protagonist Therapeutics beats FibroBiologics on 9 of the 11 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
